RSS   Newsletter   Contact   Advertise with us
Post Online Media

Critical Outcome Technologies appoints CEO

Critical Outcome TechnologiesCritical Outcome Technologies, a clinical stage biopharmaceutical company, announced that it has appointed Alison Silva as the company's next chief executive officer from January 1, 2017.
Article continues below

READ MORE K3 appoints Stuart Darling as director

Ms. Silva has worked with COTI in various roles since 2013, during which time she has been integral in shaping the Company's orphan drug development strategy.

Ms. Silva joined COTI's Board of Directors and management team in May 2015 and has been the Company's President since July 2016.

Prior to joining COTI, she was Co-founder, Executive Vice President and Chief Operating Officer of Synlogic. She is also Co-founder of The Orphan Group.

Ms. Silva's expertise spans U.S. corporate and clinical operations as COO of SLA Pharma; Drug and Business Development as VP at Marina Biotech and Cequent Pharmaceuticals; and various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts.

Ms. Silva holds a Bachelor's degree from Clark University and a Master's degree from Clark University and UMass Medical Center.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy